Board member and chairman of the board
Read more
Board member and Chairman of the Board since 2016.
Born: 1960
Education and experience: Bachelor of Science in medical microbiology from the University of Manchester and Master of Science in Management and Economics from the University of London, as well as a Fellow from the London Business School Sloan Program. Simon Cartmell has over 40 years of experience in senior executive and board positions in both private and listed companies in the pharmaceutical, biotech, medtech and diagnostic sectors.
Other current roles: Board positions at Oviva AG, Axis Spine Technology Ltd., Route2Advisors Ltd. and Route2Property Ltd.
Holdings in OssDsign: 125 000 shares and 651 273 subscription options.
Simon Cartmell is independent in relation to the Company, the Company management and the Company's major shareholders.
Board member
Read more
Board member since 2024.
Born: 1965
Education and experience: Christer Fåhraeus has thirty years of experience as CEO, board member, and chairman from fast-growing listed and unlisted companies in Life Science and Tech. He is also the founder of companies such as CellaVision AB, FlatFrog Laboratories AB, EQL Pharma AB, Anoto Group AB, Precise Biometrics AB, and Fåhraeus Startup and Growth AB. He has accumulated more than 200 years of combined board experience from listed and unlisted companies.
Medical Candidate and Ph.D. in Neurophysiology from the Faculty of Medicine at Lund University, Master of Science in Medical Engineering from the University of California San Diego (USA), and equivalent to five years of full-time studies in Mathematics and Physics at Lund University and LTH (Engineering Physics). Graduate of the Swedish Armed Forces Interpreter Academy and holds an honorary Doctorate of Technology from Lund University of Technology.
Founder of EQL Pharma AB. Chief Executive Officer 2006 – 2022, thereafter Chairman (2022 -). Board member since 2006. Chairman of the Remuneration Committee.
Other current roles: Chairman of FSG Fund II AB, Fåhraeus Startup & Growth AB, and ApoEco Sverige AB. Board member of Airsonett AB, CellaVision AB, Checkin.com Group AB, FlatFrog Laboratories AB, Melius Pharma AB, and Bionamic AB.
Holdings in OssDsign: -
Christer Fåhraeus is independent in relation to the Company and company management and in relation to the Company's major shareholders.
Board member
Read more
Board member since 2022.
Born: 1966
Education and experience: MBA in Finance and Business Management from Stern School of Business at New York University, BS in Business Administration from Questrom School of Business at Boston University, provides the board with more than 20 years of expertise and experience in the healthcare industry with extensive knowledge in spine, orthobiologics and neuromodulation. Jill has a direct experience in global medical device commercialization, launching innovative technologies, strategic marketing, healthcare consumerism and patient care pathway modeling. During her career, Jill has held leadership roles with major healthcare companies such as Johnson & Johnson and Baxter, as well as serving as an executive at high-growth, innovative companies such as AxoGen (US Nasdaq: AXGN) and ApaTech (UK), a company she helped divest to Baxter and Avation Medical.
Other current roles: CEO and Board Member Avation Medical, Board Member InteloMed, Inc.
Holdings in OssDsign: 183 270 subscription options.
Jill Schiaparelli is independent in relation to the Company and company management and in relation to the Company's major shareholders.
Board member
Read more
Board member since 2025.
Born: 1973
Education and experience: Master's degree in biomedical engineering and 2 years of economics studies. Previously worked as a management consultant in the healthcare sector in Switzerland and Sweden and as CEO in several medium-sized companies in the healthcare sector.
Other current roles: CEO of Alumbra Group AB, board member of MedCap AB (publ) and chairman of Bioswed Scientific AB.
Holdings in OssDsign: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.
David Jern is independent in relation to the company and its management as well as in relation to major shareholders.
Board member
Read more
Board member since 2025.
Born: 1970
Education and experience: Tomas Blomquist has more than 30 years of international experience in the healthcare sector, with a particular focus on Life Science Tools, Diagnostics, and Medtech. He has held executive positions at global companies such as Abbott, Roche, Johnson & Johnson, and Analyticon Biotechnologies. Tomas served as CEO and President of Biotage AB from 2019 until January 2024. He has also been a member of management teams and boards in several international companies. Tomas possesses extensive expertise in corporate strategy, vision and culture, team and leadership development, business model innovation, M&A, internationalization, organizational design, and commercialization. He holds an education from the Stockholm School of Economics, where he completed the Advanced Management Program as well as the Executive Management Program.
Other assignments: Tomas is a board member of Nolato AB (since May 2021).
Holdings in OssDsign: Does not own, directly or indirectly, shares or share-related instruments in OssDsign.
Tomas Blomquist is independent in relation to the company and its management as well as in relation to major shareholders.
